Daiichi Sankyo’s 6-Month Operating Profit Falls 32% on Higher SGA Costs for Enhertu, ADC R&D Spending

Daiichi Sankyo suffered a 32.1% drop on group operating profit in April-September as it saw increased SGA expenses tied to its antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and hefty R&D spending for its overall ADC program, according to its...read more